Atypical and malignant hidradenomas: A histological and immunohistochemical study

Modern Pathology

Volumn 22, Issue 4, 2009, Pages 600-610

  Nazarian, Rosalynn M ^a   Kapur, Payal ^b   Rakheja, Dinesh ^b,c   Piris, Adriano ^a   Duncan, Lyn M ^a   Mihm, Martin C ^a   Hoang, Mai P ^a,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

^c CHILDREN S MEDICAL CENTER   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Atypical hidradenoma; Epidermal growth factor receptor; Her2 neu; Ki 67; Malignant hidradenoma; Phosphorylated histone H3

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HISTONE H3; KI 67 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HIDRADENOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SWEAT GLAND CARCINOMA; UTERUS CARCINOMA;

EID: 63949087055     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2009.18     Document Type: Article

References (30)

1. Wong TY, Suster S, Nogita T, et al. Clear cell eccrine carcinomas of the skin. A clinicopathologic study of nine patients. Cancer 1994;15:1631-1643.
2. Ko CJ, Cochran AJ, Eng W, et al. Hidradenocarcinoma: a histological and immunohistochemical study. J Cutan Pathol 2006;33:726-730.
3. Berg J, McDivitt RW. Pathology of sweat gland carcinoma. Pathol Annu 1968;3:123-144.
4. Keasbey LE, Hadley GG. Clear-cell hidradenoma: report of three cases with widespread metastases. Cancer 1954;7:934-952.
5. Hernandez-Parez E, Cestoni-Parducci R. Nodular hidradenoma and hidradenocarcinoma. A 10-year review. J Am Acad Dermatol 1985;12:15-20.
6. Headington JT, Niederhuber JE, Beals TF. Malignantclear cell acrospiroma. Cancer 1978;41:641-647.
7. Santa Cruz DJ. Sweat gland carcinomas: a comprehensive review. Semin Diagn Pathol 1987;4:38-74.
8. Kersting DW. Clear cell hidradenoma and hidradenocarcinoma. Arch Dermatol 1963;87:323-333.
9. Mehregan AH, Hashimoto K, Rahbari H. Eccrine adenocarcinoma: a clinicopathologic study of 35 cases. Arch Dermatol 1983;119:104-114.
10. Chung CK, Hefferman AH. Clear cell hidradenoma with metastasis: case report with a review of the literature. Plast Reconstr Surg 1971;48:177-179.
11. Mambo NC. The significance of atypical nuclear changes in benign eccrine acrospiromas: a clinical and pathological study of 18 cases. J Cutan Pathol 1984;11:35-44.
12. Ansai S, Koseki S, Hozumi Y, et al. Assessment of cellular proliferation of eccrine acrospiromas and eccrine sweat gland carcinomas by AgNOR counting and immunohistochemical demonstration of proliferating cell nuclear antigen (PCNA) and Ki-67. Clin Exp Dermatol 1995;20:27-34.
13. Khurshid A, Yaquoob N, Devan HA, et al. 'Nuclear groove' in nodular hidradenoma: frequency and significance of an unrecognized histopathological feature. J Cutan Pathol 2007;34:871-875.
14. Janisson-Dargaud D, Durlach A, Lorenzato M, et al. Aneuploidy, but not Ki-67 or EGFR expression, is associated with recurrences in basal cell carcinoma. J Cutan Pathol 2008;35:916-921.
15. Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133:1710-1715.
16. Aoyagi S, Akiyama M, Shimizu H. High expression of Ki-67 and cyclin D1 in invasive extramammary Paget's disease. J Dermatol Sci 2008;50:177-184.
17. Sugiyama A, Sugiura M, Piris A, et al. Apocrine cystadenoma and apocrine hidrocystoma: examination of 21 cases with emphasis on nomenclature according to proliferative features. J Cutan Pathol 2007;12:912-917.
18. Gurley LR, D'Anna JA, Barham SS, et al. Histone phosphorylation and chromatin structure during mitosis in Chinese hamster cells. Eur J Biochem 1978;84:1-15.
19. Ribalta T, McCutcheon IE, Aldape KD, et al. The mitosis-specific antibody anti-phosphohistone H3 (PHH3) facilitates rapid reliable grading of meningiomas according to WHO 2000 criteria. Am J Surg Pathol 2004;28:1532-1536.
20. Davidson EJ, Morris LS, Scott IS, et al. Minichromosome maintenance (Mcm) proteins, cyclin B1 and D1, phosphohistone H3 and in situ DNA replication for functional analysis of vulval intraepithelial neoplasia. Br J Cancer 2003;88:257-262.
21. Scott IS, Heath TM, Morris LS, et al. A novel immunohistochemical method for estimating cell cycle phase distribution in ovarian serous neoplasms: implications for the histopathological assessment of paraffin-embedded specimens. Br J Cancer 2004;90: 1583-1590.
22. Holbro T, Civenni G, Hynes NE. The ErbB receptors and their role in cancer progression. Exp Cell Res 2003;284:99-110.
23. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001;37(Suppl 4):S9.
24. Wang SE, Narasanna A, Perez-Torres M, et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosinase kinase inhibitors. Cancer Cell 2006;10:25-38.
25. Li D, Ambrogo L, Shimamura T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008;27: 4702-4711.
26. Riely GJ. Second-generation epidermal growth factor receptor tyrosinase kinase inhibitors in non-small cell lung cancer. J Thorac Oncol 2008;3(Suppl 2): S146-S149.
27. Nash JW, Barrett TL, Kies M, et al. Metastatic hidradenocarcinoma with demonstration of Her-2/ neu gene amplification by fluorescence in situ hybridization: potential treatment implications. J Cutan Pathol 2007;34:49-54.
28. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists Guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007;131:18.
29. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists Guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-145.
30. Parra HS, Cavina R, Latteri F, et al. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer. Br J Cancer 2004;91:208-212.